Press Release May 26 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Pemetrexed for Injection. This drug is used to treat certain types of cancers, including lung cancer and mesothelioma. The approval allows Zydus to market the drug in various strengths and will be manufactured at Zydus Hospira.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release May 13 2022
- Press Release May 06 2022
- Press Release May 03 2022
- Press Release Apr 26 2022
- Press Release Apr 25 2022
Later from Zydus Lifesciences
- Press Release May 27 2022
- Press Release Jun 06 2022
- Press Release Jun 07 2022
- Press Release Jun 30 2022
- Press Release Jul 08 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences